Mostrando entradas con la etiqueta cancer. Mostrar todas las entradas
Mostrando entradas con la etiqueta cancer. Mostrar todas las entradas

martes, 1 de mayo de 2012

Bladder cancer diagnosis encourages smokers to quit - Oncology Nurse Advisor

(HealthDay News) -- Smokers with a new diagnosis of bladder cancer are significantly more likely to quit compared with smokers in the general population, according to a study published online April 23 in the Journal of Clinical Oncology.

Jeffrey C. Bassett, M.D., M.P.H., from the University of California in Los Angeles, and colleagues investigated the impact of a bladder cancer diagnosis on patterns of tobacco use and smoking cessation in a random sample of noninvasive bladder cancer survivors diagnosed in 2006. A total of 344 respondents of 492 eligible participants completed a survey on tobacco use (70 percent response rate) and were compared by smoking status. To ascertain the impact of cancer diagnosis on tobacco use, respondents who smoked at diagnosis were compared with general population controls from the California Tobacco Survey.

The researchers found that 74 percent of respondents had a history of cigarette use, and 17 percent were smokers at the time of diagnosis. Smokers with a new diagnosis of bladder cancer were significantly more likely to quit (48 percent) than smokers in the general population (10 percent) (P < 0.001). The reasons most often cited for smoking cessation were bladder cancer diagnosis and advice of the urologist. When a urologist was the source of their understanding, respondents were more likely to endorse smoking as a risk factor for bladder cancer.

"Given the negative impact that continued smoking has on recurrence, progression, morbidity, and mortality, each diagnosis of bladder cancer in a smoker should be viewed as an opportunity to help them quit their tobacco use for good," the authors conclude.

Abstract
Full Text (subscription or payment may be required)


View the original article here

Canada Adds Warning for Actos Bladder Cancer as U.S. Actos Lawsuits Mount - Albany Times Union

The Actos Resource Center is the Web’s largest source for information on Actos research, side effects and legal news. Visit http://www.ActosCancer.com

(PRWEB) April 27, 2012

The Actos Resource Center, a consumer advocacy group, is alerting patients in the United States of an additional warning issued over the safety of Actos by Canada’s top drug regulatory agency.

Health Canada issued a warning on April 19, 2012 that the diabetes drug Actos may cause an increased risk of bladder cancer. Authorities there also stated they had come to an agreement with Takeda Pharmaceuticals, maker of the drug, to add a label warning addressing the risk.

The Canadian agency functions in much the same way as the FDA in the United States, who issued a similar warning associating Actos with bladder cancer on June 15, 2011.

According to The Canadian Press on April 19, 2012, the latest warning was issued in response to a study by Health Canada which was commenced last June, finding users of Actos are more than 40% more likely to develop bladder cancer.

The news is the latest in a string of warnings over Actos. Last year, CBS News reported on June 10, 2011 that Germany and France had banned Actos prescriptions after a study by the French Medicines Agency indicated long-term use could increase bladder cancer occurrences by as much as 40 percent.

In the United States, Takeda faces growing litigation concerns. Bloomberg reported on March 13, 2012 that as many as 10,000 patients may eventually file an Actos bladder cancer lawsuit. In December, a federal Judicial Panel on Multidistrict Litigation issued an order consolidating all lawsuits to a federal court in Louisiana. The case is known as In Re: Actos Products Liability Litigation, MDL 2299, U.S. District Court, Western District of Louisiana (Lafayette).

The Actos Resource Center urges anyone who has taken Actos to monitor for bladder cancer symptoms, and anyone who has been affected by bladder cancer to learn about their legal options.

The Actos Bladder Cancer Center only works with qualified Actos lawyers named to the Actos Plaintiff Steering Committee leading this litigation.

For more information on the research, warnings, side effects and legal news pertaining to the drug Actos, or for a recommendation of the top Actos lawyers, visit ActosCancer.com.

For the original version on PRWeb visit: http://www.prweb.com/releases/prwebactos/bladder-cancer/prweb9437804.htm


View the original article here

Canada Adds Warning for Actos Bladder Cancer as U.S. Actos Lawsuits Mount - Virtual-Strategy Magazine

 The Actos Resource Center is the Web’s largest source for information on Actos research, side effects and legal news. Visit http://www.ActosCancer.com(PRWEB) April 27, 2012


The Actos Resource Center, a consumer advocacy group, is alerting patients in the United States of an additional warning issued over the safety of Actos by Canada’s top drug regulatory agency.


Health Canada issued a warning on April 19, 2012 that the diabetes drug Actos may cause an increased risk of bladder cancer. Authorities there also stated they had come to an agreement with Takeda Pharmaceuticals, maker of the drug, to add a label warning addressing the risk.


The Canadian agency functions in much the same way as the FDA in the United States, who issued a similar warning associating Actos with bladder cancer on June 15, 2011.


According to The Canadian Press on April 19, 2012, the latest warning was issued in response to a study by Health Canada which was commenced last June, finding users of Actos are more than 40% more likely to develop bladder cancer.


The news is the latest in a string of warnings over Actos. Last year, CBS News reported on June 10, 2011 that Germany and France had banned Actos prescriptions after a study by the French Medicines Agency indicated long-term use could increase bladder cancer occurrences by as much as 40 percent.


In the United States, Takeda faces growing litigation concerns. Bloomberg reported on March 13, 2012 that as many as 10,000 patients may eventually file an Actos bladder cancer lawsuit. In December, a federal Judicial Panel on Multidistrict Litigation issued an order consolidating all lawsuits to a federal court in Louisiana. The case is known as In Re: Actos Products Liability Litigation, MDL 2299, U.S. District Court, Western District of Louisiana (Lafayette).


The Actos Resource Center urges anyone who has taken Actos to monitor for bladder cancer symptoms, and anyone who has been affected by bladder cancer to learn about their legal options.


The Actos Bladder Cancer Center only works with qualified Actos lawyers named to the Actos Plaintiff Steering Committee leading this litigation.


For more information on the research, warnings, side effects and legal news pertaining to the drug Actos, or for a recommendation of the top Actos lawyers, visit ActosCancer.com.


For the original version on PRWeb visit: http://www.prweb.com/releases/prwebactos/bladder-cancer/prweb9437804.htm 


View the original article here

lunes, 30 de abril de 2012

Diabetes drug may pose bladder cancer risk: Health Canada - CTV.ca

Diabetes drug may pose bladder cancer risk: Health Canada




TORONTO — Taking the diabetes drug Actos may increase one's risk of developing bladder cancer, Health Canada and the drug's maker, Takeda Canada Inc., said in a warning issued Thursday.


The statement was the culmination of a safety assessment Health Canada announced last June, two days after the U.S. Food and Drug administration issued a warning similar to the one the Canadian drug regulator just announced.


Health Canada said the drug's labelling will be changed to reflect the potential risk.


Actos is the brand name for pioglitazone, a drug from the glitazone family used for the treatment of Type 2 diabetes. It is a sister drug to Avandia, a once widely used diabetes drug that fell out of favour after studies found it increased users' risk of heart disease.


While it was thought that Actos was safer than Avandia -- at least in terms of heart disease -- there have been suggestions for awhile that using the drug, especially long-term, might increase one's risk of developing bladder cancer.


Takeda is conducting a 10-year study trying to see if the link is real. Data from the midway point of the study points to the possibility that it is, Health Canada said in its statement.


Dr. Muhammad Mamdani, director of the Applied Health Research Centre of the Li Ka Shing Knowledge Institute at Toronto's St. Michael's Hospital, said the warning likely won't impact that many people, because doctors have been moving their patients off the drug over the past few years.


In fact, in Ontario Actos is no longer on the list of drugs that doctors can freely prescribe; it has been moved to the "exceptional access" list and can only be prescribed with approval, Mamdani said.


Dr. David Juurlink, head of the division of clinical pharmacology at the University of Toronto, said at this point there is little need to resort to this drug, unless a patient has done extraordinarily well on it in the past.


"I personally would not be comfortable using it as a long-term therapy because bladder cancer is ... not something that's reversible. It's not a skin rash that goes away when you stop the drug," said Juurlink, who actively campaigned to get Avandia out of use.


"We've got other options. And when you've got other options why would you take an option that has some well-established side-effects and some side-effects that are less well established but ones that you would for sure rather avoid?"


Juurlink suggested that anyone taking the drug who has concerns about this news should speak to their doctor.


The Health Canada statement noted that in the Takeda trial, people who weren't using the drug developed bladder cancer at a rate of about seven cases in every 10,000 people. But there were 10 cases per 10,000 people among the people using Actos for control of Type 2 diabetes.


The statement says the risk appears to be highest for people who took the drug for the longest duration or at the highest dosages, but it isn't possible to rule out a risk even after short-term use.


The drug regulator suggests that Actos should not be used to treat patients with active bladder cancer, a history of bladder cancer or uninvestigated blood in their urine.


It also suggested doctors should assess a patient's risk for bladder cancer before starting treatment with this drug. Known risk factors include age, smoking, a family history of bladder cancer, exposure to chemicals in the workplace, certain cancer treatments and radiation therapy.


Share with your social Network:


View the original article here

Neoadjuvant Chemotherapy Urged for Rare Type of Bladder Cancer - Renal and Urology News

Neoadjuvant chemotherapy for patients with small cell urothelial carcinoma (SCUC) improves their likelihood of survival compared with a historical cohort of patients treated with initial cystectomy, a study found.

Based on the study's findings, researchers concluded that neoadjuvant chemotherapy should be considered for all patients with surgically resectable SCUC.

Investigators at the M.D. Anderson Cancer Center in Houston led by Arlene Siefker-Radtke, MD, studied 95 SCUC patients who were surgical candidates. Of these, 48 received neoadjuvant chemotherapy and 47 underwent initial surgery. The median overall and disease-specific survival were significantly greater in the adjuvant chemotherapy recipients than those who had initial surgery (159.5 vs. 18.3 months and 79% vs. 20%, respectively), according to a report in European Urology (published online ahead of print).

Adjuvant chemotherapy had no impact on overall survival among patients treated with initial cystectomy, although the small number of patients limits the impact of this finding. The median overall survival for those treated and not treated with adjuvant chemotherapy was 18.1 vs. 18.3 months, respectively.

“Neoadjuvant chemotherapy for SCUC is associated with a high rate of pathologic downstaging and correlates significantly with higher survival as compare to historical expectations,” the authors wrote. “With initial surgery, there is an increased risk of pathologic upstaging, at times leading to an aborted cystectomy and resulting in poor outcomes.”

Neoadjuvant chemotherapy resulted in pathologic downstaging in 62% of tumors compared with only 9% for those who underwent initial surgery.

View the original article here

Spectrum says bladder cancer drug fails, buys Allos - Reuters

(Reuters) - Spectrum Pharmaceuticals Inc (SPPI.O) said its experimental drug to treat a common form of bladder cancer failed to significantly reduce the recurrence of tumors in late-stage trials, sending its shares down 14 percent.


Separately, the biotechnology company said it agreed to buy Allos Therapeutics (ALTH.O) for about $206 million to gain access to its anti-cancer drug Folotyn.


Spectrum was testing the drug apaziquone in two late-stage trials for non-muscle invasive bladder tumors (NMIBC), which are currently removed through surgery.


NMIBC is a form of bladder cancer localized in the surface layers of the bladder. About 70 percent of all patients diagnosed with bladder cancer have NMIBC.


Patients in the late-stage trials either received a single dose of apaziquone or a placebo into the bladder after the surgery.


Spectrum, which is developing the drug with medical device maker Allergan Inc (AGN.N), said the drug failed to show a statistically significant difference in the rate of tumor recurrence at two years against a placebo.


The company, however, said the pooled data from both studies showed a statistically significant treatment effect.


Spectrum said it plans to meet the U.S. Food and Drug Administration to discuss further steps.


"It is unusual for the FDA to review the NDA (new drug application) with the pooled data, but it is possible," said MLV & Co analyst George Zavoico.


Zavoico said in an email that MLV expects to receive or intends to seek compensation for investment banking services from Spectrum in the next three months.


DEAL TERMS


Allos shareholders will get $1.82 in cash for each share, which represents a premium of 27 percent to Allos' Wednesday close, plus a contingent value right that gives shareholders 11 cents, if certain regulatory and sales milestones are met in Europe.


Allos' lead drug Folotyn, which is used to treat relapsed or refractory peripheral T-cell lymphoma, raked in sales of about $50 million last year. The drug had been rejected by an European advisory committee and the company had submitted a request to re-examine its application.


The committee is expected to issue its decision in the second quarter of this year.


On a conference call with analysts, Spectrum's Chief Executive Rajesh Shrotriya said Folotyn annual sales could cross $100 million.


MLV's Zavoico said the drug could reach $100 million sales, especially if they get European approval.


Spectrum, which also makes lymphoma drug Zevalin, expects the deal to save about $40 million to $50 million in 2013.


"Folotyn is prescribed by the same physicians who prescribe Zevalin," said Shrotriya. A salesman selling two products would bring down expenses.


Last year, AMAG Pharmaceuticals Inc (AMAG.O) had dropped its plan to buy Allos after AMAG shareholders opposed the deal.


Spectrum expects to close the deal in the second quarter and add to its fourth-quarter earnings. The company expects to finance the acquisition with a combination of cash on hand and a revolving credit line from Bank of America.


Spectrum is advised by RBC Capital Markets and Allos by J.P. Morgan Securities.


Spectrum shares were down 10 percent at $11.03 in morning trade on Nasdaq, while Allos rose to $1.82.


(Reporting by Anand Basu in Bangalore; Editing by Don Sebastian)


View the original article here

Survival rates for most cancer victims improve - Yorkshire Post


Published on Thursday 26 April 2012 20:25

MORE cancer patients are surviving longer after treatment for the disease but significant differences remain depending on where people live, according to a new report.

Figures published yesterday by the Office for National Statistics show five-year survival rates improved for all cancers diagnosed in men between 2001-2005 except for bladder cancer where there was no improvement.

Survival rates among women improved for cancers of the colon, lung and breast but remained stable after five years for cancers of the cervix, bladder, oesophagus and stomach.

The largest increase in five-year survival over the period was for cancer of the colon.

But the figures again exposed significant differences in survival rates between the 28 cancer networks in England.

Some 19.3 per cent of patients with stomach cancer treated in the Yorkshire cancer network, which covers West Yorkshire and parts of North Yorkshire, survived five years, which is the best performance outside London.

But a third fewer people with the condition survived to 2010 if they were treated in the Humber and Yorkshire Coast network and in the North Trent network, which covers South Yorkshire and the north Midlands.

There were also big disparities in prostate cancer survival, with 82.1 per cent of patients living five years in the Yorkshire network, falling to 69.4 per cent in North Trent – the worst performance in the country.

Survival among breast cancer patients, which is the most common cancer, was broadly similar with around 83 per cent living five years, the highest rate for any of the cancers.

In contrast, patients with lung cancer were least likely to survive, with around only one in 13 patients diagnosed from 2001-5 living five years.

Sarah Cant, head of policy and campaigns at The Prostate Cancer Charity, said it was encouraging survival rates were improving.

“However, they also clearly highlight that there are still regional variations in the survival rates of men with prostate cancer across the country and even across Yorkshire,” she added.

The charity was campaigning to ensure men with the illness got the same care and support wherever they lived.

“We’re calling on the Government to urgently set out the standard of care men with this disease need at every stage of their journey. Men with prostate cancer deserve the best and we want to make sure that’s exactly what they get,” she said.

Nick Ormiston-Smith, of the charity Cancer Research UK, said the figures also highlighted variations in one-year cancer survival rates which indicated how well the disease was being diagnosed and treated promptly.

“Thanks to developments in cancer research we now have better treatments and overall cancer survival is improving,” he said.

“There is still much more to do to ensure that every cancer patient – no matter their age or where they live – has the best possible chance of surviving the disease.

“Spotting potential cancer symptoms early is vital if we are to achieve this.”

Rates of survival vary for a number of different reasons including age, lifestyle and late presentations by patients with the illness but some disparities are likely to be due to variations in treatment.

Cancer survival rates in the UK remain controversial amid criticism they are lower than in Europe and other parts of the world.

The Department of Health last year published figures which pointed to a significant gap in survival despite improvements in treatment in the last decade.

It set out a strategy to improve outcomes, with the aim of saving an additional 5,000 lives every year by 2014-15.



View the original article here

lunes, 19 de marzo de 2012

Baylor coach Drew and his siblings lead cheers in parents&apos; cancer fights - PennLive.com

ALBUQUERQUE, N.M. _ Basketball has always represented common ground for the Drew clan _ family business, touchstone, emotional outlet.


As the Drews faced their most difficult personal moment this fall and winter, basketball was again at the center of the struggle. Former Valparaiso University basketball coach Homer Drew was diagnosed with prostate cancer in September. Three days later, Janet, his wife of 44 years, was found to have advanced stage 3 bladder cancer.


The terrible news was a 1-2 punch to a close-knit family that includes son Scott, the head coach at Baylor. Homer Drew's cancer was not necessarily a shock, given that his father had died from the disease and that he underwent regular tests. Janet's diagnosis blindsided everyone.


"You expected one bad news, but two at the same time.....," Scott Drew said. "That was a tough day."


Six months later, Homer is cancer free. Janet, finishing radiation treatment, received encouraging medical news last week that led to an impromptu celebration after son Bryce coached Valparaiso to the Horizon League regular-season title.


Basketball served as a welcome diversion, Homer Drew said. He and his wife still live Valparaiso, a northern Indiana town of 31,730. They followed Bryce's team in person, and used satellite to catch almost all of Baylor's games from afar.


"It was a wonderful release," Homer Drew said in a phone interview as his wife napped. "It gave something for both of us to be involved in and for both of us to look forward to. We went from doctor to hospital to game. That was the pattern for three months."


If there is a first family of March Madness buzzer-beaters, it may be the Drews.


Tuesday marked the 14th anniversary of one of the most famous shots in NCAA Tournament history. Bryce Drew's jump shot off a long inbounds pass helped Valparaiso edge Mississippi in the first round of the 1998 tournament.


Homer was coaching the 13th-seeded Crusaders. Scott, the oldest child, was an assistant and rising star in coaching as his father's heir apparent.


Sister Dana was a standout player at Toledo, good enough to have her jersey retired this season.


While his two siblings were dealing with their parents' illness, Scott was trying to multitask nearly 900 miles away, coaching a top-10 program with high expectations while trying to do what he could for his parents.


He learned the intricacies of Skype and FaceTime to help his three children bond with their grandparents, calling nearly every day.


"I knew they were always watching our game, and I was trying to put them in a good mood by winning," he said. "It's hard enough when you compete. When you know how much it means to family, friends and loved ones among you, it makes you want to even compete that much harder."


He also immersed himself in cancer research. Scott can recite the ominous numbers about men over 40 and prostate cancer, along with the remarkable medical advances in treating bladder cancer. His mother had a replacement bladder that doctors built from part of her small intestine.


He also gained an appreciation for his father, whose initial surgery went well and who then took on the primary caregiver role for his wife.


Early on, Janet Drew told her husband: "This is the toughest coaching job you'll ever have."


Suddenly, he was confronted with a world of catheters and stents _ and even shopping. Janet drew her recently retired husband a map of the local grocery store, complete with arrows marking milk and bread.


"To see him take care of her makes me proud to be his son," Scott said. "I hope I can be a father like that someday."


Added Bryce, whose team fell to Miami in the NIT on Wednesday: "They don't have to say any words. Seeing how they've gone through teaches me hundreds of lessons."


Just more than three weeks ago, on Feb. 21, the Drew family got an answer to their hopes and prayers.


Because cancer had been found in Janet's lymph nodes, doctors were concerned about a possible spread to the brain and lungs.


MRI scans of her brain and torso revealed no further cancer.


"She's always been the rock and foundation of the family," Homer said, praising her courage and faith. "It's amazed us how she tackled it day in and day out with the difficult surgery and recovery."


Scott got the good news by phone but had a surprise for his mom. He, his wife and three children were in Valparaiso. After Bryce's team beat Loyola of Chicago to win the Horizon League, the entire family of three children and seven grandchildren surprised Janet in Bryce's office.


The family hopes for better news next week when the radiation treatment ends and Janet is examined again.


"It definitely brings you closer any time there's a struggle in the family and seeing your mom and dad going through tough times physically and not able to do the things they would want to," Scott said. "It makes everybody realize how quickly life passes and how you have to enjoy every day."


___


(c)2012 The Dallas Morning News


Visit The Dallas Morning News at www.dallasnews.com


Distributed by MCT Information Services


View the original article here

domingo, 18 de marzo de 2012

Run/walk against bladder cancer is Saturday in Oswego - Syracuse.com

Oswego, NY -- A run/walk to raise money to fight bladder cancer is being held at 10 a.m. Saturday in Oswego.

The "Run for Dennis" event honors Dennis Pacheco, of Oswego, who died of the disease March 17, 2011. A native of Rome, he was a long-time employee at the James FitzPatrick Nuclear Plant, coached soccer and baseball teams when his three children were young, was an avid motorcyclist and enjoyed motorsports, hunting, construction, woodworking and playing harmonica. He also liked all types of music, but especially enjoyed the blues and was known to do an impromptu Elvis impersonation on many occasions.

The race course is a 5K (3.1 miles) and begins at Gibby’s Irish Pub on Lake Street.

Go to this website link to register for the race. The cost now is $25 and $30 on Saturday morning.

Packet pickup is from 5 to 8 p.m. Friday at Gibby’s Irish Pub, 8 W. Second st., Oswego. Packet pickup also is available from 8 to 9:30 a.m. on race day.

Proceeds go to the Bladder Cancer Advocacy Network. Donations can be made to "Run For Dennis" and sent to Oswego County Federal Credit Union, P.O. Box 310, Oswego, 13126.


View the original article here

Summary of the 6th annual bladder cancer think tank: New directions in ... - UroToday

UroToday - Summary of the 6th annual bladder cancer think tank: New directions in urologic research - Abstract var base_url="http://www.urotoday.com/";
MARCH 17, 2012 Username

Password

Remember MeSubscribeForgot your password?Forgot your username? Quicklinks CAUTI ChallengeBladder Cancer Diagnosis & Monitoring CenterAdvanced Prostate Cancer Treatment Resource centerGU MalignanciesProstate CancerBladder CancerOveractive BladderFemale UrologyInfections advanced search HOMEConference CoverageEvent CalendarAdvanced SearchUroToday International Journal Browse CategoriesInvestigational UrologyProstate CancerRenal CancerBladder CancerEtiologyEpidemiologySymptoms & SignsDiagnosisPathologyNatural HistoryStagingBladder Cancer Diagnosis & Monitoring CenterCases, Prevalence, & MortalityGuidelines -Conference CoverageLinksTesticular CancerPenis & Urethra CancerBPH & Male LUTSErectile Dysfunction (ED)ProstatitisMale Infertility & ReproductionUrinary Incontinence (UI)Overactive BladderStress Urinary Incontinence (SUI)Female UrologyPeyronie's DiseaseIC/PBS/BPS/HBSStone DiseaseInfectionsUrologic Trauma and ReconstructionRenal Transplantation, Vascular DiseaseAdrenal and RetroperitoneumPediatric UrologyRelated TopicsGeriatric UrologyLaparoscopic & RoboticAndrogen DeficiencySexually Transmitted DiseaseDisease ResourcesFemale Sexual DysfunctionPelvic Floor RehabilitationCurrent Clinical Trials Home > Bladder Cancer #wrapper_photos,#mod_localnews_sports,#weather_photos{display:none;} Summary of the 6th annual bladder cancer think tank: New directions in urologic research - Abstract Thu, 15 March 2012 E-mail Print The 6th Annual Bladder Cancer Think Tank brought together a multidisciplinary group of clinicians, researchers, and representatives from the National Cancer Institute and Industry in an effort to advance bladder cancer research efforts.Username

Password

Remember MeSubscribeForgot your password?Forgot your username?
Your session will expire in 8 hours requiring you to log in each day to view content.
SUBMIT COMMENTS  * Please keep your comments relevant to the subject of the article
* The editors cannot answer queries or questions posted as comments
* Questions pertaining to specific health issues should be directed to a physician or medical professional

User Name: Your Title:Comment:

Verification: Type the characters you see in the picture below. Share| SubscribeNew User Create ProfileLogin & Subscribe NowSubscription InformationManage Your SubscriptionFAQsAbout UsEditors CornerBlogSlide LibraryPublication OpportunitiesUroToday ExclusivesBJU Int Mini ReviewsPublication LibraryGeneral FAQsBeyond the AbstractFeatured Conference

XXXIII Brazilian Congress of Urology

November 22 - 26, 2011
Santa Catarina, Brazil

Read More

4th World Congress on Controversies in Urology (CURy)

January 27 - 30, 2011

Paris, France

Read MoreUpcoming Conference

27th Annual European Association of Urology (EAU) Congress

February 24 - 28, 2012

Paris, France

Read More Home About Us About The Editors Sponsorship Opportunities Terms of Use Privacy Policy Services Report an Inaccuracy contact us Conference Highlights Events Resources Surgical Library Publication Library Slide Library Current Clinical Trials Links Case Studies Podcasts Centers of Excellence CAUTI Center Bladder Cancer Diagnosis & Monitoring Center GU Malignancies Center for Stones Disease Advanced Prostate Cancer Treatment Resource Center Careers + Training Educational Opportunities Sponsorship and Training Programs Position Offerings UroToday International Journal The Experts Digital Science Press Inc., 1741 Eighth Street, Berkeley, CA 94710 USA | fax: 510 540 0930  | E: info@urotoday.com | ISSN 1939-4810 | UroToday International Journal Correspondence

View the original article here

RhoGDI2 protein helps prevent bladder cancer metastasis to the lungs - News-Medical.net

The diagnosis of localized bladder cancer carries an 80 percent five-year survival rate, but once the cancer spreads, the survival rate at even three years is only 20 percent. A major study published today in the Journal of Clinical Investigation not only shows how bladder cancer metastasizes to the lungs but pinpoints a method for stopping this spread.

Specifically, the study shows that versican, a protein involved in cancer cell migration, is a driver of lung metastasis and that high levels of versican are associated with poor prognosis in bladder cancer patients. The study is the first to show how that when a cancer cell makes the protein RhoGDI2, it reduces the cell's production of versican, thus blocking the ability of the cancer cell to grow in the lungs.

"For a decade, we've known that the major challenge of treating bladder cancer is treating or preventing the metastatic form of the disease. This study represents an advance in the latter - by preventing the spread of bladder cancer to the lungs, we could improve patient survival," says Dan Theodorescu, MD, PhD, director of the University of Colorado Cancer Center, the paper's senior author.

When a cancer metastasizes from its birth location to another, it's not necessarily that cells suddenly become mobile and thus able to float through the blood or lymph to new homes. In fact, these cancer cells may have been floating through a patient's blood for quite some time, and metastasis occurs only when one of these intrepid cells is finally able to grow in the place where it is attached, such as the lungs.

When the first cancer cells to attach to, say, the lung, they have a tough time - they become distressed. Cancer cells express this distress in the form of versican. And the more versican they express, the more help they get, which arrives in the form of macrophages, a part of the body's immune response that eat pathogens and other debris.

In most cases, the fact that macrophages benefit distressed cells is good, but in addition to helping healthy cells survive, these arriving macrophages also promote the growth of cancer cells that have landed in distant sites such as the lung, thus promoting metastasis of the disease.

More versican made by the cancer cells calls more macrophages, which aid cancer cells' survival and increase the likelihood that a cancer cell's toehold will develop into a clinically significant tumor in the lung.


View the original article here